This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shah, U. Articles by Hayes, D. N. Search for Related Content PubMed PubMed Citation Articles by Shah, U. Articles by Hayes, D. N. Related Collections Cellular Pathobiology Cellular Pathobiology: Metabolism and Physiology

LKB1 and Lung Cancer: More Than the Usual Suspects

Departments of ¹ Medicine and ² Genetics, The Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina

Requests for reprints: D. Neil Hayes, The Lineberger Comprehensive Cancer Center, Department of Medicine CB# 7295, The University of North Carolina School of Medicine, Chapel Hill, NC 27599-7295. Phone: 919-966-3786; Fax 919-966-1587; E-mail: hayes{at}med.unc.edu.

Key Words: KRAS • LKB1 • lung cancer

Often, the problem in cancer research is figuring out how a gene or pathway works in regulating cellular transformation. The question of what RAS activates or PTEN inhibits have been classic dilemmas of modern cancer biology. In these cases, biochemical and genetic studies have provided us with a fairly clear picture of the cancer relevant functions of these genes. For LKB1, a more recently identified human tumor suppressor gene, however, the problem is different. This serine-threonine kinase that is conserved from yeast to mammals seems to play a role in many diverse cellular pathways. Therefore, although elegant functional and genetic approaches have established critical roles for LKB1 in the regulation of metabolism, motility, polarity, and the cell cycle, the role(s) responsible for its true tumor suppressor function(s) is unknown. One is reminded of an Agatha Christie murder mystery where nearly every character in the book has reason to be suspected of committing the crime—there are too many suspects for how LKB1 might repress lung cancer. [Cancer Res 2008;68(10):3562–5]

This article has been cited by other articles:

				S. Regina, J.-B. Valentin, S. Lachot, E. Lemarie, J. Rollin, and Y. Gruel Increased Tissue Factor Expression Is Associated with Reduced Survival in Non-Small Cell Lung Cancer and with Mutations of TP53 and PTEN Clin. Chem., October 1, 2009; 55(10): 1834 - 1842. [Abstract] [Full Text] [PDF]

				M. Jansen, J. P. ten Klooster, G. J. Offerhaus, and H. Clevers LKB1 and AMPK Family Signaling: The Intimate Link Between Cell Polarity and Energy Metabolism Physiol Rev, July 1, 2009; 89(3): 777 - 798. [Abstract] [Full Text] [PDF]

				H. Ebi, S. Tomida, T. Takeuchi, C. Arima, T. Sato, T. Mitsudomi, Y. Yatabe, H. Osada, and T. Takahashi Relationship of Deregulated Signaling Converging onto mTOR with Prognosis and Classification of Lung Adenocarcinoma Shown by Two Independent In silico Analyses Cancer Res., May 1, 2009; 69(9): 4027 - 4035. [Abstract] [Full Text] [PDF]

				L. J. Inge, K. D. Coon, M. A. Smith, and R. M. Bremner Expression of LKB1 tumor suppressor in non-small cell lung cancer determines sensitivity to 2-deoxyglucose. J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 580 - 586. [Abstract] [Full Text] [PDF]

				R. S. Herbst, J. V. Heymach, and S. M. Lippman Lung Cancer N. Engl. J. Med., September 25, 2008; 359(13): 1367 - 1380. [Full Text] [PDF]